DB
KZR

Dmitry Balyasny’s Kezar Life Sciences KZR Stock Holding History

Dmitry Balyasny’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,983
Closed -$280K – 2924
2022
Q4 		$280K Buy
3,983
+2,358
+145% +$175K ﹤0.01% 2019
2022
Q3 		$140K Sell
1,625
-1,375
-46% -$134K ﹤0.01% 2368
2022
Q2 		$248K Buy
+3,000
New +$265K ﹤0.01% 2155

Other funds holding KZR

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Dmitry Balyasny's KZR Position: Q1 2023 in Review

Dmitry Balyasny sold out of Kezar Life Sciences (KZR) in Q1 2023, closing a stake of 3,983 shares — an estimated $280K sold.

Dmitry Balyasny first reported a position in KZR in Q2 2022 and held it in 3 quarters. The position peaked at $280K in Q4 2022. 136 funds tracked by Wall St. Rank hold KZR as of Q1 2023.

  • Dmitry Balyasny reported no remaining Kezar Life Sciences position as of Q1 2023 after selling out during the quarter.
  • Dmitry Balyasny sold 3,983 Kezar Life Sciences shares in Q1 2023, an estimated $280K.
  • Dmitry Balyasny first reported a position in Kezar Life Sciences in Q2 2022 and held it in 3 quarters.
  • Dmitry Balyasny's Kezar Life Sciences position peaked at $280K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.